{
  "id": 225604,
  "title": "Single dose of psilocybin for depression shows promising results in UK's first publicly funded randomized trial",
  "url": "https://urgent.news/2026/08/06/single-dose-of-psilocybin-for-depression-shows-promising-results-in",
  "topic": "science",
  "section": "Science",
  "published": "2026-08-06T15:20:05.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-08-dose-psilocybin-depression-results-uk.html"
  },
  "original_language": "en",
  "account": "A UK-funded study has revealed that a single dose of psilocybin, the active compound found in magic mushrooms, may effectively alleviate severe depression for which standard treatments have failed. The trial, known as PsiDeR, marks the first publicly funded randomized test of its kind to occur within an NHS setting in England. Participating in the study were 60 individuals grappling with treatment-resistant depression, a condition that hasn't responded to at least two prior therapies. Half of the volunteers received a 25 mg psilocybin dose, while the other half received a placebo. Both groups also received psychological support. Neither participants nor researchers were aware of who was in which group. At three weeks, those who took psilocybin achieved significantly greater drops in depression scores, as measured by the Montgomery-Åsberg Depression Rating Scale, compared to those who received the placebo. By six weeks, 50% of the psilocybin group met the criteria for treatment response, compared to just 3% of the placebo group. Similarly, the rates of depression remission—when symptoms fall low enough not to meet clinical criteria—were 40% in the psilocybin group versus 3% in the placebo group, both at three weeks and sustained at six weeks. Professor James Rucker, the study's lead investigator, stated that the randomized trial of psilocybin versus a true placebo proved feasible for participants who often failed many treatments. The trial found that those who received the psilocybin dose were much more likely to improve than those who received placebo up to six weeks. Publicly funded clinical trials are crucial for evidence supporting a new intervention's place in real-world practice. The trial also demonstrated that psilocybin can be administered safely in community settings, outside of a hospital environment.",
  "summary": "The first randomized controlled trial in the U.K. has found that a single dose of psilocybin, the active compound found in \"magic mushrooms,\" produced significant improvements in depression compared with a placebo. This is the first publicly funded randomized trial of its kind to deliver the treatment within an NHS setting in England, and it found promising results.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}